{"entity":{"id":"alethia-biotherapeutics","kind":"company","name":"Alethia Biotherapeutics","aka":["Alethia Biotherapeutics Inc."],"tldr":"Alethia Biotherapeutics is a Montreal biotech whose antibody sotevtamab (AB-16B5) blocks secreted clusterin, a protein that lets lung and other cancers change shape, spread and resist treatment.","summary":"Alethia Biotherapeutics develops sotevtamab (AB-16B5), a humanised antibody against secreted clusterin, a chaperone protein that promotes epithelial-to-mesenchymal transition. Blocking it is intended to keep tumour cells in an epithelial state that responds better to chemotherapy and immunotherapy. Sotevtamab is in a phase 2 trial with docetaxel in non-small cell lung cancer after platinum and checkpoint therapy, and has been studied in other solid tumours.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sotevtamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Montreal","country":"CA","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/alethia-biotherapeutics/","neighbours":{"drug":[{"id":"sotevtamab","kind":"drug","name":"Sotevtamab","route":"/drugs/sotevtamab/"}]}}